What is BiVACOR?
Founded in 2008 and headquartered in Houston, Texas, BiVACOR® is a medical device manufacturer dedicated to developing advanced healthcare solutions. The company boasts a team of world-class engineers, medical specialists, and business executives committed to pushing the boundaries of medical technology. BiVACOR has cultivated a robust collaborative network, both nationally and internationally, to support its mission.
How much funding has BiVACOR raised?
BiVACOR has raised a total of $22M across 2 funding rounds:
Grant
$3M
Series B
$19M
Grant (2021): $3M with participation from National Heart, Lung, and Blood Institute at the U.S. National Institute of Health
Series B (2021): $19M led by OneVentures and Cormorant Asset Management
Key Investors in BiVACOR
National Heart, Lung, and Blood Institute at the U.S. National Institute of Health
A key governmental research institute focused on advancing the understanding, prevention, and treatment of heart, lung, and blood diseases.
OneVentures
OneVentures is an Australian venture capital firm that invests in high-growth technology and life science companies, providing strategic capital and support for innovation.
Cormorant Asset Management
Cormorant Asset Management is a life sciences investment firm specializing in providing financial resources to innovative publicly traded and private companies in the biotech and allied sectors.
What's next for BiVACOR?
The substantial enterprise-level investment positions BiVACOR for accelerated growth and market expansion. This strategic backing is expected to fuel further research and development, enhance manufacturing capabilities, and broaden the company's reach within the medical device sector. The company's focus on a ground-breaking technology suggests a trajectory towards significant market disruption and improved patient outcomes.
See full BiVACOR company page
